Firm settles FTC charges
This article was originally published in The Tan Sheet
An FTC order directs Sagee U.S.A. Group to pay $10,000 in redress to settle charges of making false and unsubstantiated claims for its eponymous product. The order includes a $1.38 mil. avalanche clause that would be put into effect if the firm misrepresents its financial state. Original claims stated that Sagee could improve brain health, revitalize and rejuvenate the brain and alleviate or treat a number of serious, chronic brain-related diseases, including schizophrenia, Alzheimer's and Parkinson's disease. The firm advertised the supplement through radio, TV, print and internet media to the Chinese and Vietnamese-speaking communities. The order also requires various recordkeeping provisions to aid FTC in future monitoring the firm's compliance...
You may also be interested in...
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?